Coronavirus disease-2019 (COVID-19) and the associated pathophysiological perturbations continue to bewilder the fraternity at large. In this context, the thromboembolic predisposition in COVID-19 has particularly emerged as a matter of an ardent debate. The index commentary aims to present an account of the recent developments in the understanding of the immunothrombosis in the enigmatical setting of COVID-19.
Magoon R. COVID-19 related strokes: Pandora's Box may open as the p(c)lot thickens! [March 19, 2021]. Neurologia 2021;36(7):562–563. DOI: 10.1016/j.nrl.2021.03.004.
Magoon R. COVID-19 and congenital heart disease: cardiopulmonary interactions for the worse! Paediatr Anaesth 2020;30(10):1160–1161. DOI: 10.1111/pan.14004.
Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med 2021;16(2):309–312. DOI: 10.1007/s11739-020-02601-y.
Bachler M, Bösch J, Stürzel DP, Hell T, Giebl A, Ströhle M, et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth 2021;126(3):590–598. DOI: 10.1016/j.bja.2020.12.010.
Heinz C, Miesbach W, Herrmann E, Sonntagbauer M, Raimann FJ, Zacharowski K, et al. Greater fibrinolysis resistance but no greater platelet aggregation in critically ill COVID-19 patients. Anesthesiology 2021;134(3):457–467. DOI: 10.1097/ALN.0000000000003685.
Magoon R. Pulmonary vasculature in COVID-19: mechanism to monitoring! Korean J Anesthesiol 2021;74(2):186–187. DOI: 10.4097/kja.20536.
Görlinger K, Levy JH. COVID-19-associated coagulopathy. Anesthesiology 2021;134(3):366–369. DOI: 10.1097/ALN.0000000000003688.
Görlinger K, Dirkmann D, Gandhi A, Simioni P. COVID-19-associated coagulopathy and inflammatory response: what do we know already and what are the knowledge gaps? Anesth Analg 2020;131(5):1324–1333. DOI: 10.1213/ANE.0000000000005147.
Kwaan HC, Lindholm PF. The central role of fibrinolytic response in COVID-19: a hematologist's perspective. Int J Mol Sci 2021;22(3):1283. DOI: 10.3390/ijms22031283.
Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019;9(1):19. DOI: 10.1186/s13613-019-0499-6.
Görlinger K, Almutawah H, Almutawaa F, Alwabari M, Alsultan Z, Almajed J, et al. The role of rotational thromboelastometry during the COVID-19 pandemic: a narrative review. Korean J Anesthesiol 2021;74(2):91–102. DOI: 10.4097/kja.21006.
Weiss E, Roux O, Moyer JD, Paugam-Burtz C, Boudaoud L, Ajzenberg N, et al. Fibrinolysis resistance: a potential mechanism underlying COVID-19 coagulopathy. Thromb Haemost 2020;120(9):1343–1345. DOI: 10.1055/s-0040-1713637.
Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost 2020;18(7):1752–1755. DOI: 10.1111/jth. 14828.
Wu Y, Wang T, Guo C, Zhang D, Ge X, Huang Z, et al. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. QJM 2020113(8):539–545. DOI: 10.1093/qjmed/hcaa121.
Magoon R. Implications of practice variability: comment. Anesthesiology 2020;133(4):943–944. DOI: 10.1097/ALN.0000000000003465.
